Hormonal

Teriparatide

Also known as: Forteo, PTH 1-34

FDA Approved
Share:

Key Facts: Teriparatide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Osteoporosis
Administration
Subcutaneous injection daily
Typical Dose
20 mcg daily
Frequency
Once daily
Evidence Level
FDA Approved
Duration
Maximum 2 years (lifetime limit due to osteosarcoma concern)
Also Known As
Forteo, PTH 1-34

What to Expect

A recombinant fragment of parathyroid hormone that stimulates bone formation. FDA approved for osteoporosis with high fracture risk.

Mechanism of Action

Teriparatide contains amino acids 1-34 of PTH. Intermittent dosing stimulates osteoblasts more than osteoclasts, resulting in net bone formation. This anabolic effect differs from antiresorptive osteoporosis drugs.

Research Summary

Fracture Prevention Trial showed 65% reduction in vertebral fractures. Only bone-building (anabolic) therapy available until abaloparatide. Increases bone mineral density more effectively than bisphosphonates initially.

Clinical Status:FDA Approved - Osteoporosis
Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

20 mcg daily

Range

20 mcg daily

Frequency

Once daily

FDA-approved PTH analog for osteoporosis. Max 2 years treatment. Injection in thigh or abdomen.

Research Dosing

Scientific studies

FDA-approved dosing

Doses from Studies

Duration

Maximum 2 years (lifetime limit due to osteosarcoma concern)

Administration

Subcutaneous injection daily

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Joint pain (10%)
  • Nausea
  • Headache
  • Dizziness
  • Leg cramps
  • Injection site reactions
  • Orthostatic hypotension
  • Hypercalcemia
  • BOXED WARNING: Osteosarcoma risk - limit to 2 years
  • FDA approved (Forteo)

References

Related Peptides

Peptides commonly compared with Teriparatide or used in similar applications.

Want updates on Teriparatide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Educational Information Only

This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.